Cadrenal Therapeutics, Inc. Common Stock (CVKD) 是一家上市公司 属于 医疗保健 板块，经营于 生物科技 行业. 公司总部位于 Ponte Vedra, FL, 美国. 现任CEO为 Quang X. Pham.
CVKD 拥有 IPO日期为 2023-01-20, 4 名全职员工, 在 NASDAQ Global Market, 市值为 $12.01M.
Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel therapy with orphan drug indication for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation. The company was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.
